Elicio Therapeutics ELTX Cash Flow Statement (2019-2026)

NASDAQ ELTX
$1.63 +0.02 (+1.24%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

Elicio Therapeutics Quarterly Cash Flow Statement

Periods 28 quarters
Latest Sep 2026

Elicio Therapeutics reported cash from operations of -$10.36M and free cash flow of -$10.36M for the quarter ended Sep 2026, up 6.5% year over year. This cash flow statement covers 28 quarters of results from Dec 2019 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income
14.89M-7.06M-7.30M-7.20M-6.65M-8.03M-7.56M-10.66M-8.95M-11.83M-7.23M-18.84M-14.00M-11.21M-10.56M-10.08M-7.72M-11.82M-8.22M-7.98M
Depreciation and DepletionDep. & Depletion
0.04M0.03M0.15M0.10M0.10M0.11M0.10M0.10M0.10M0.10M0.09M0.10M0.10M0.10M0.00M0.05M0.10M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
0.03M0.05M0.04M0.18M0.07M0.06M0.10M
Depreciation & Amortization (CF)Dep. & Amort.
0.04M0.03M0.15M0.10M0.10M0.11M0.10M0.10M0.10M0.10M0.09M0.10M0.10M0.10M0.00M0.05M0.10M
Share-based CompensationStock Comp.
2.02M0.03M0.24M0.11M0.20M0.22M0.28M0.34M0.34M0.32M0.35M0.31M0.46M0.52M0.71M0.70M0.77M0.87M0.94M1.11M
Gains from Equity InvestmentsGains Equity
-0.17M0.01M0.13M0.01M
Gains from Sales and DivestituresGains Divest
0.00M0.00M-0.11M0.00M
Gains from Investment SecuritiesGains Investment
-0.36M-0.66M0.11M0.32M
Cash from Restructuring
0.00M
Other non-cash itemsOther Non-Cash
-0.11M0.16M0.28M0.34M-0.58M-0.01M0.19M2.06M-3.62M8.54M0.98M0.84M0.86M1.81M-1.52M1.23M-2.48M-0.71M
Change in Working Capital
Change in Account PayablesChange Payables
-2.94M-1.32M3.08M-0.35M-0.28M1.39M-1.46M0.14M-0.04M-3.26M-0.05M0.93M-0.95M3.00M-0.17M-3.54M0.35M-0.46M0.63M-0.46M
Change in Accrued ExpensesChange Accrued Exp.
-2.17M2.02M-1.91M-0.18M-0.24M-0.38M0.12M2.16M0.31M-0.43M2.04M-0.51M3.56M-2.65M-0.66M0.11M1.21M-0.60M1.47M-1.32M
Change in Other Operating AssetsOther Assets Change
0.91M0.68M-0.78M1.50M0.47M1.02M0.07M-1.05M0.69M-1.25M0.18M-0.59M-1.42M0.00M-1.39M0.51M-0.11M0.73M0.58M1.13M
Change in Other Operating LiabilitiesOther Liabilities Change
-25.34M-1.64M1.42M2.00M-0.87M-0.67M-1.10M1.41M-1.21M-0.31M-0.53M0.75M-0.35M-0.70M-0.91M-0.23M-0.23M-0.24M-0.25M-0.26M
Other Working Capital ChangesOther WC Changes
-26.26M-2.32M2.20M0.50M-1.35M-1.69M-1.18M2.46M-1.90M0.93M-0.71M1.34M1.07M-0.71M0.49M-0.74M-0.13M-0.97M-0.84M-1.39M
Cash from OperationsCash from Ops.
-14.36M-15.65M6.14M-5.39M-7.28M-8.14M-9.48M-5.19M-9.90M-12.12M-8.93M-7.27M-8.74M-10.12M-8.95M-11.09M-6.80M-11.65M-8.17M-10.36M
Investing Activities
Capital ExpendituresCapex
0.04M0.56M0.10M0.02M0.00M0.05M0.04M0.05M0.02M
Sales of Property, Plant and EquipmentPP&E (Sale)
0.03M0.00M
Change in Property, Plant and EquipmentChange in PP&E
-0.04M-0.56M-0.10M-0.02M0.03M-0.05M0.00M-0.04M-0.05M-0.02M
Sale and Maturity of InvestmentsInvestments Sold
-0.03M
Other Investing Activities (as filed)Other investing (as filed)
0.62M2.15M-0.51M-10.00M10.68M1.67M-0.95M1.35M-0.27M0.93M-0.14M1.38M-0.68M0.00M0.00M0.71M-0.19M
Cash from Investing ActivitiesCash from Investing
-0.04M-0.56M-0.10M-0.02M0.03M-0.05M0.00M-0.04M-0.05M-0.02M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
0.30M10.00M19.73M9.14M9.87M
Long-Term Debt RepaymentsLT Debt Repayment
0.01M0.01M0.02M0.01M0.02M0.02M
Net Long-Term Debt Issued (Repaid)Net LT Debt
0.29M-0.01M-0.02M-0.01M-0.02M9.99M19.73M9.14M9.87M
Net Debt Issuances and RepaymentsNet Debt Issuance
0.29M-0.01M-0.02M-0.01M-0.02M9.99M19.73M9.14M9.87M
Change in Capital Stock
Common Stock IssuedStock Issued
-2.98M0.08M-0.06M0.07M0.04M0.03M0.06M7.00M11.02M0.32M11.58M-12.34M0.35M0.05M1.04M16.25M0.10M0.02M13.58M
Net Shares Issued and RepurchasedNet Shares Issued
-2.98M0.08M-0.06M0.07M0.04M0.03M0.06M7.00M11.02M0.32M11.58M-12.34M0.35M0.05M1.04M16.25M0.10M0.02M13.58M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
8.84M11.11M
Net Equity Issued and RepurchasedNet Equity Issued
-57.72M0.08M8.78M11.18M0.04M0.03M0.06M7.00M11.02M0.32M11.58M-12.34M0.35M0.05M1.04M16.25M0.10M0.02M13.58M
Other financing activities (as filed)
3.07M-0.23M-2.14M0.00M-0.55M
Cash from Financing ActivitiesCash from Financing
0.40M-0.01M1.26M8.78M11.18M10.04M21.51M0.06M7.00M11.02M0.32M30.75M0.23M10.33M11.93M9.57M4.86M8.03M16.51M17.79M
Additional items
Exchange Rate EffectFX Effect
0.01M-0.09M0.09M0.08M-0.08M0.00M-0.04M0.04M0.03M0.03M0.07M0.04M-0.10M0.01M0.00M0.00M
Change in Cash
-13.98M-15.75M6.93M3.39M3.81M1.88M12.07M-5.17M-2.89M-1.10M-8.70M23.52M-8.54M0.24M3.06M-1.48M-2.05M-3.61M8.34M7.42M
Ending Cash Balance
10.05M73.00M1.22M4.61M8.41M10.30M22.36M17.20M14.30M13.21M4.51M28.03M19.49M19.73M22.79M21.31M19.27M15.65M24.00M31.42M
Free Cash FlowFCF
-14.40M-15.65M5.58M-5.39M-7.37M-8.16M-9.48M-5.23M-9.90M-12.12M-8.97M-7.27M-8.79M-10.12M-8.95M-11.09M-6.81M-11.65M-8.17M-10.36M
Net Cash FlowNCF
-13.99M-15.67M6.84M3.39M3.81M1.88M12.07M-5.17M-2.89M-1.10M-8.65M23.48M-8.56M0.21M2.98M-1.51M-1.95M-3.62M8.35M7.42M
Income Taxes PaidTaxes Paid

Elicio Therapeutics Cash Flow Statement API

Pull Elicio Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=ELTX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY